CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Prabhudas Lilladher recommended reduce rating on Dr. Reddy's Laboratories with a target price of Rs 1335 in its research ...

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' ...

Dr Reddy's Laboratories shares dropped nearly 7% on Friday after the company reported a slight increase in net profit for the ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...

Dr Reddy’s Laboratories reports 2% increase in net profit, attributing growth to new acquisitions and product launches.

Dr Reddy's Laboratories reported a 2% increase in net profit to Rs 1,413 crore for the third quarter ending December 2024.

Pharmaceutical major Dr Reddy's Laboratories Ltd on Thursday (January 23) reported a 2.5% year-on-year (YoY) increase in net ...